Granted Patent
B2
US 12,594,290 · App. 19/065,860 · Granted Apr 7, 2026
IP and IP analogs dosage regimens for the treatment of ectopic calcifications
Inventors:
Joan Perello Bestard (Palma de Mallorca, ES); Carolina Salcedo Roca (Palma de Mallorca, ES); Ana-Zeralda Canals Hamann (Palma de Mallorca, ES)
Assignee:
SANIFIT THERAPEUTICS S.A.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
Claims (21)
1 . A method of treating or inhibiting the occurrence of aortic stenosis in a human subject in need thereof, comprising administering a dosage of about 5 mg to 10 mg of SNF472 (hexasodium salt of myo-inositol hexaphosphate) per kg per day, wherein the administration of the dosage effectively treats or inhibits the occurrence of aortic stenosis in the subject.
2 . The method of claim 1 , wherein the dosage is administered daily.
3 . The method of claim 2 , wherein the dosage is administered daily to the subject for about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 weeks.
4 . The method of claim 1 , wherein SNF472 is at least 90% pure.
5 . The method of claim 1 , wherein SNF472 is at least 95% pure.
6 . The method of claim 5 , wherein SNF472 is at least 99% pure.
7 . The method of claim 1 , wherein the dose of SNF472 is formulated for injection.
8 . The method of claim 7 , wherein the injection is an intravenous injection.
9 . The method of claim 8 , wherein the intravenous injection is a bolus injection.
10 . The method of claim 9 , wherein the intravenous injection is intravenous infusion.
11 . The method of claim 10 , wherein the administration is via slow or controlled release.
12 . The method of claim 1 , wherein the dosage is administered as a single daily dose or as multiple daily doses.
13 . The method of claim 1 , wherein the dosage is administered between 2, 3, 4, 5, 6, or 7 times per week.
14 . The method of claim 13 , wherein the dosage is administered 3 times per week.
15 . The method of claim 1 , wherein the dosage is administered for 12 weeks.
16 . The method of claim 1 , wherein the dosage is administered 3 days per week for 12 weeks.
17 . The method of claim 1 , wherein the subject has end-stage renal disease and/or is on hemodialysis.
18 . The method of claim 1 , wherein the dosage is administered via a dialysis apparatus.
19 . The method of claim 18 , wherein the dosage is administered before or after the filter of the dialysis apparatus.
20 . The method of claim 1 , wherein the administration of the dosage to the subject inhibits the formation and/or growth of hydroxyapatite crystals.
21 . The method of claim 1 , wherein the dosage of about 5 mg to 10 mg of SNF472 (hexasodium salt of myo-inositol hexaphosphate) per kg per day is a unit dose of about 6.0 mg/kg, about 7.0 mg/kg, about 8.0 mg/kg, about 9.0 mg/kg, about 9.7 mg/kg, or about 10 mg/kg.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 10, 2025
From: BESTARD, JOAN PERELLO; ROCA, CAROLINA SALCEDO; HAMANN, ANA-ZERALDA CANALS
To: SANIFIT THERAPEUTICS S.A.
Reel/Frame 073173/0560 →
NUNC PRO TUNC ASSIGNMENT
Recorded Jul 8, 2025
From: SANIFIT THERAPEUTICS, S.A.
To: VIFOR (INTERNATIONAL) LTD.
Reel/Frame 071859/0562 →
Priority Claims (1)
ES ES201830988
· Oct 11, 2018
· national
Continuity (5)
Continuation
18778767
· Jul 19, 2024
Continuation
PCTIB2018057904
· Oct 11, 2018
References Cited (320)
US 3159581A
· Diehl
· 1964
[cited by applicant]
US 3488419A
· Mccune et al.
· 1970
[cited by applicant]
US 3934001A
· Watson
· 1976
[cited by applicant]
US 3934002A
· Haefele
· 1976
[cited by applicant]
US 4024175A
· Satzinger et al.
· 1977
[cited by applicant]
US 4215105A
· Gaffar et al.
· 1980
[cited by applicant]
US 4259316A
· Nakashima et al.
· 1981
[cited by applicant]
US 4515772A
· Parran, Jr. et al.
· 1985
[cited by applicant]
US 4627977A
· Gaffar et al.
· 1986
[cited by applicant]
US 4752586A
· Ropars et al.
· 1988
[cited by applicant]
US 4808401A
· Gaffar et al.
· 1989
[cited by applicant]
US 4826675A
· Gaffar et al.
· 1989
[cited by applicant]
US 4952568A
· Sawai et al.
· 1990
[cited by applicant]
US 5007790A
· Shell
· 1991
[cited by applicant]
US 5015634A
· Siren
· 1991
[cited by applicant]
US 5041429A
· Sawai et al.
· 1991
[cited by applicant]
US 5057507A
· Siren
· 1991
[cited by applicant]
US 5082833A
· Shamsuddin
· 1992
[cited by applicant]
US 5112814A
· Sabin
· 1992
[cited by applicant]
US 5206226A
· Sabin
· 1993
[cited by applicant]
US 5268176A
· Znaiden et al.
· 1993
[cited by applicant]
US 5300289A
· Garlich et al.
· 1994
[cited by applicant]
US 5330979A
· Siren et al.
· 1994
[cited by applicant]
US 5362886A
· Berglund
· 1994
[cited by applicant]
US 5516801A
· Horrobin et al.
· 1996
[cited by applicant]
US 5552148A
· Znaiden et al.
· 1996
[cited by applicant]
US 5582837A
· Shell
· 1996
[cited by applicant]
US 5821237A
· Bissett et al.
· 1998
[cited by applicant]
US 5972389A
· Shell et al.
· 1999
[cited by applicant]
US 6121243A
· Lanzendorfer et al.
· 2000
[cited by applicant]
US 6340475B2
· Shell et al.
· 2002
[cited by applicant]
US 6359194B1
· Galvin et al.
· 2002
[cited by applicant]
US 6451808B1
· Cowles
· 2002
[cited by applicant]
US 6488962B1
· Berner et al.
· 2002
[cited by applicant]
US 6610702B2
· Lehn et al.
· 2003
[cited by applicant]
US 8277909B2
· Simpson et al.
· 2012
[cited by applicant]
US 8377909B2
· Grases Freixedas et al.
· 2013
[cited by applicant]
US 8778912B2
· Grases Freixedas et al.
· 2014
[cited by applicant]
US 9155750B2
· Grases Freixedas et al.
· 2015
[cited by applicant]
US 9358243B2
· Castagner et al.
· 2016
[cited by applicant]
US 9364490B2
· Perello Bestard et al.
· 2016
[cited by applicant]
US 9612250B2
· Perello Bestard et al.
· 2017
[cited by applicant]
US 9629872B2
· Ratsimbazafy et al.
· 2017
[cited by applicant]
US 9751903B2
· Castagner et al.
· 2017
[cited by applicant]
US 20020051820A1
· Shell et al.
· 2002
[cited by applicant]
US 20030039688A1
· Shell et al.
· 2003
[cited by applicant]
US 20030104053A1
· Gusler et al.
· 2003
[cited by applicant]
US 20030119910A1
· Kamiya et al.
· 2003
[cited by applicant]
US 20030147952A1
· Lim et al.
· 2003
[cited by applicant]
US 20060241086A1
· Nicolau et al.
· 2006
[cited by applicant]
US 20070066574A1
· Grases Freixedas
· 2007
[cited by applicant]
US 20070148258A1
· O'Neill et al.
· 2007
[cited by applicant]
US 20070212449A1
· Shamsuddin et al.
· 2007
[cited by applicant]
US 20070219115A1
· Coleman et al.
· 2007
[cited by applicant]
US 20100113613A1
· Mclaurin et al.
· 2010
[cited by applicant]
US 20110091440A1
· Sabin
· 2011
[cited by applicant]
US 20110293595A1
· Sabin
· 2011
[cited by applicant]
US 20130302448A1
· Parc
· 2013
[cited by applicant]
US 20170119799A1
· Grases Freixedas et al.
· 2017
[cited by applicant]
US 20170360810A1
· Perello Bestard et al.
· 2017
[cited by applicant]
US 20190167702A1
· Perello Bestard et al.
· 2019
[cited by applicant]
US 20220000889A1
· Bassissi et al.
· 2022
[cited by applicant]
US 20220249521A1
· Perello Bestard et al.
· 2022
[cited by applicant]
US 20220339171A1
· Perello Bestard et al.
· 2022
[cited by applicant]
US 20230248749A1
· Bassissi et al.
· 2023
[cited by applicant]
US 20240066042A1
· Perello Bestard et al.
· 2024
[cited by applicant]
US 20250295676A1
· Perello Bestard et al.
· 2025
[cited by applicant]
CA 2975801A1
· 2010
[cited by applicant]
CN 1295862A
· 2001
[cited by applicant]
CN 1593376A
· 2005
[cited by applicant]
DE 29910454U1
· 1999
[cited by applicant]
EP 1203535A1
· 2002
[cited by applicant]
EP 2324835A2
· 2011
[cited by applicant]
EP 2974714A1
· 2016
[cited by applicant]
EP 3407891A1
· 2018
[cited by applicant]
GB 2055574A
· 1981
[cited by applicant]
WO WO9011757A1
· 1990
[cited by applicant]
WO WO1991009601A1
· 1991
[cited by applicant]
WO WO9318755A1
· 1993
[cited by applicant]
WO WO9747285A1
· 1997
[cited by applicant]
WO WO9811879A1
· 1998
[cited by applicant]
WO WO9855107A1
· 1998
[cited by applicant]
WO WO0113933A2
· 2001
[cited by applicant]
WO WO0124830A2
· 2001
[cited by applicant]
WO WO0132217A2
· 2001
[cited by applicant]
WO WO0156544A2
· 2001
[cited by applicant]
WO WO0197783A1
· 2001
[cited by applicant]
WO WO0209723A2
· 2002
[cited by applicant]
WO WO0210177A1
· 2002
[cited by applicant]
WO WO0232416A2
· 2002
[cited by applicant]
WO WO0296404A1
· 2002
[cited by applicant]
WO WO0335029A1
· 2003
[cited by applicant]
WO WO0335039A1
· 2003
[cited by applicant]
WO WO0335040A1
· 2003
[cited by applicant]
WO WO0335041A1
· 2003
[cited by applicant]
WO WO0335177A2
· 2003
[cited by applicant]
WO WO2004015084A2
· 2004
[cited by applicant]
WO WO2005044278A1
· 2005
[cited by applicant]
WO WO2007023306A1
· 2007
[cited by applicant]
WO WO2013050603A1
· 2013
[cited by applicant]
WO WO2017098033A1
· 2017
[cited by applicant]
WO WO2017098047A1
· 2017
[cited by applicant]
WO WO2017131127A1
· 2017
[cited by applicant]
WO WO2020074944A1
· 2020
[cited by applicant]
WO WO2020157362A1
· 2020
[cited by applicant]
WO WO2021094331A1
· 2021
[cited by applicant]
Angelis, M., et al., “Calciphylaxis in patients on hemodialysis: a prevalence study,” Surgery 122(6): 1083-1090, Elsevier, Netherlands (Dec. 1997).
[cited by applicant]
Augustin, M., et al. “Quality-of-life evaluation in chronic wounds: comparative analysis of three disease-specific questionnaires,” International Wound Journal 14(6): 1299-1304, John Wiley, United States (Dec. 2017).
[cited by applicant]
Avogaro, A., and Fadini, G. P., “Mechanisms of ectopic calcification: implications for diabetic vasculopathy,” Cardiovascular Diagnosis and Therapy 5(5): 343-52, AME Publishing Company, China (Oct. 2015).
[cited by applicant]
Bhambri, A., and Del Rosso, J. Q., “Calciphylaxis: a review,” Journal of Clinical and Aesthetic Dermatology 1(2): 38-41, Matrix Mexical Communications, United States (Jul. 2008).
[cited by applicant]
Brandenburg, V., et al. “Fo020 A Phase 2 Open-Label Single-Arm Study To Assess The Effect Of Snf472 On Wound Healing In Calciphylaxis (Calcific Uremic Arteriolopathy) Patients,” Nephrology Dialysis Transplantation 33(su…
[cited by applicant]
Brandenburg, V., et al., “Phase 2 Open Label Single Arm Repeat Dose Study To Assess The Effect Of SNF472 On Wound Healing In Uraemic Calciphylaxis Patients,” Sepsis 1: 8-3, Kluwer Academic Publishers, Netherlands (May 2…
[cited by applicant]
Brater, D. C., “Measurement of renal function during drug development,” British Journal of Clinical Pharmacology 54(1):87-95, Blackwell Science Ltd., United Kingdom (Jul. 2002).
[cited by applicant]
Budisavljevic, M. N., et al., “Calciphylaxis in chronic renal failure,” Journal of the American Society of Nephrology 7(7): 978-982, American Society of Nephrology, United States (Jul. 1996).
[cited by applicant]
Costa-Bauza, A., et al., “An experimental study on residual lithiasis after shock wave lithotripsy,” Urological Research 33(1):51-56, Springer-Verlag, Germany (Feb. 2005).
[cited by applicant]
Davita, “Kidney Stones and Chronic Kidney Disease,” accessed at http://www.davita.com/kidney-disease/overview/symptoms-and-diagnosis/kidney-stones-a, accessed on Nov. 5, 2015, 2 pages.
[cited by applicant]
Dolhofer, R. and Wieland, O. H., “Enzymatic assay of myo-inositol in serum,” Journal of Clinical Chemistry and Clinical Biochemistry 25(10):733-736, Walter De Gruyter & Co., Germany (1987).
[cited by applicant]
Espacenet, English-language Machine Translation of German Patent DE29910454 (cited herewith as FP1), performed on Apr. 24, 2017, 7 pages.
[cited by applicant]
Fine, A., and Zacharias, J., “Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy,” Kidney International 61(6): 2210-2217, Elsevier, Netherlands (Jun. 2002).
[cited by applicant]
Fuster, J. M. B., et al., “Plant phosphates, phytate and pathological calcifications in chronic kidney disease,” Nefrologia 37(1):20-28, Elsevier, Netherlands (Jan. 2017).
[cited by applicant]
Giachelli, C. M., “Ectopic calcification: gathering hard facts about soft tissue mineralization,” American Journal of Pathology 154(3): 671-675, American Society for Investigative Pathology, United States (Mar. 1999).
[cited by applicant]
Grases, F., and Costa-Bauza, A., “Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment,” Anticancer Research 19(5A):3717-3722, International Insti…
[cited by applicant]
Grases, F. and March, P., “A Study about Some Phosphate Derivatives as Inhibitors of Calcium Oxalate Crystal Growth,” Journal of Crystal Growth 96(4):993-995, Elsevier Science Publishers B.V., The Netherlands (Aug. 1989…
[cited by applicant]
Grases, F., et al., “Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans,” Biofactors 15(1):53-61, IOS Press, Netherlands (2001).
[cited by applicant]
Grases, F., et al., “Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates,” Urological Research 28(2):136-140, Springer-Verlag, Germany …
[cited by applicant]
Grases, F., et al., “Effects of phytic acid on renal stone formation in rats,” Scandinavian Journal of Urology and Nephrology 32(4):261-265, Scandinavian University Press, Norway (Jan. 1998).
[cited by applicant]
Grases, F., et al., “Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats,” Frontiers in Bioscience 11:136-142, Frontiers In Bioscience Publications, United States (Jan. 2006).
[cited by applicant]
Grases, F., et al., “Phytate acts as an inhibitor in formation of renal calculi,” Frontiers in Bioscience 12:2580-2587, Frontiers In Bioscience Publications, United States (Jan. 2007).
[cited by applicant]
Green, C. J., et al., “D-myo-inositol-1, 2, 6-trisphosphate (PP56) Inhibits Lipid Peroxidation in Warm Ischaemic Rabbit Kidneys,” Medical Science Research 17(18):749-750, Elsevier Applied Science, United States (1989).
[cited by applicant]
Hafner, J., et al. “Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy,” Journal of the Am…
[cited by applicant]
Haynes, D. A., et al., “Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database,” Journal of Pharmaceutical Sciences 94(10): 2111-2120, Elsevier, Netherlands (Oct. 2005).
[cited by applicant]
Henneman, P. H., et al., “The cause of hypercalcuria in sarcoid and its treatment with cortisone and sodium phytate,” Journal of Clinical Investigation 35(11):1229-1242, American Society for Clinical Investigation, Unit…
[cited by applicant]
Hoppe, B., “An update on primary hyperoxaluria,” Nat Rev Nephrol 8(8):467-475, Macmillan Publishers Limited, United Kingdom (Jun. 2012).
[cited by applicant]
Irnell, L., “Metastatic calcification of soft tissue on overdosage of vitamin D,” Acta Medica Scandinavica 185(3):147-152, Almqvist and Wiksell, Sweden (Jan. 1969).
[cited by applicant]
Joubert, P., et al., “Hypothesis: Phytate is an important unrecognised nutrient and potential intravenous drug for preventing vascular calcification,” Medical Hypothesis 94: 89-92, Elsevier, Netherlands (Sep. 2016).
[cited by applicant]
Khakimov, Z.Z., et al., “Antioxidant Therapeutics of Acute Renal Insufficiency in Case Crush-Syndrome on Growing Rats,” Uzbekskii Biologicheskii Zhurnal 5:3-6, Publishing House “Fan” of the Academy of Sciences of the Re…
[cited by applicant]
Levin, A., et al., “Mathematical formulation to help identify the patient at risk of ischemic tissue necrosis—a potentially lethal complication of chronic renal failure,” American Journal of Nephrology 13(6): 448-453, K…
[cited by applicant]
Liu, W., et al., “Current understanding of coronary artery calcification,” Journal of Geriatric Cardiology 12(6):668-675, Institute of Geriatric Cardiology, China (Nov. 2015).
[cited by applicant]
Merriam-Webster Online Dictionary, “Prevention,” accessed at http://www.merriam-webster.com/dictionary/prevention, accessed on Oct. 16, 2020, 1 page.
[cited by applicant]
Salcedo, C., et al., “SNF472 Inhibits Heart Valve Calcification in a Novel In Vitro Method Using Porcine Whole Leaflets,” Bone and Mineral Metabolism: Basic, Abstract PO0320, Kidney Week, American Society of Nephrology,…
[cited by applicant]
Mochel, M. C., et al. “Cutaneous calciphylaxis: a retrospective histopathologic evaluation,” The American Journal of Dermatopathology 35(5): 582-586, Lippincott Williams and Wilkins Ltd., United States (Jul. 2013).
[cited by applicant]
Nigwekar, S. U., et al., “Calciphylaxis: risk factors, diagnosis, and treatment,” American Journal of Kidney Diseases 66(1): 133-146, Elsevier, Netherlands (Jul. 2015).
[cited by applicant]
O'neill, W.C., et al., “Treatment with pyrophosphate inhibits uremic vascular calcification,” Kidney International 79(5):512-517, Elsevier, United States (Mar. 2011).
[cited by applicant]
Oudshoorn, M. H. M. et al., “Synthesis and characterization of hyperbranched polyglycerol hydrogels,” Biomaterials 27(32): 5471-5479, Elsevier, Netherlands (Nov. 2006).
[cited by applicant]
Pai, M. P., “Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32(9): 856-868, Wiley and So…
[cited by applicant]
Pan, S.-D., et al. “Weight-based dosing in medication use: what should we know?,” Patient Prefer Adherence 10: 549-60, Dove Press, United Kingdom (Apr. 2016).
[cited by applicant]
Perelló, J., et al. “First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification,” Br J Clin Pharmacol 84(12): 2867-2876, Wiley…
[cited by applicant]
Phanish, M. K., et al., “Tumoral calcinosis associated with pyrexia and systemic inflammatory response in a haemodialysis patient: successful treatment using intravenous pamidronate,” Nephrol Dial Transplant 15: 1691-16…
[cited by applicant]
Phase 2 Study With SNF472 in Calciphylaxis Patients. NCT02790073, ClinicalTrials.gov, accessed at https://clinicaltrials.gov/ct2/show/NCT02790073, accessed on Oct. 9, 2020, 7 pages.
[cited by applicant]
Russo, D., et al., “Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis,” Kidney International 80:112-118, Springer-Verlag, Germany (Jul. 2011).
[cited by applicant]
Salcedo, C., et al. “A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients,” Br J Clin Pharmacol 85(4): 796-806, British Pharmacological Society, United Kingdom (Apr. 2019).
[cited by applicant]
Sanchis, P., et al., “Protective Effect of Myo-Inositol Hexaphosphate (Phytate) on Abdominal Aortic Calcification in Patients With Chronic Kidney Disease,” Journal of Renal Nutrition 26(4):226-236, Elsevier, Netherlands…
[cited by applicant]
“Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis”, accessed at https://www.sanifit.com/sanifit-announces-results-phase-ii-clinical-trial-snf472-patients-calciphylaxis/, …
[cited by applicant]
Shantouf, R. S., et al., “Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients,” American Journal of Nephrology 31(5):419-425, Karger AG, United States (Apr…
[cited by applicant]
Sircus, M., Dr., “Calcification and Its Treatment with Magnesium and Sodium Thiosulfate,” drsircus.com, accessed at drsircus.com/magnesium/calcification-and-its-treatment-with-magnesium-and-sodium-thiosulfate/, accessed…
[cited by applicant]
Sun, X. Y., et al., “Cardiovascular and renal effects of alpha-trinositol in ischemic heart failure rats,” Life Science 57(12): 1197-1211, Elsevier, Netherlands (Aug. 1995).
[cited by applicant]
Weenig, R. H., et al. “Calciphylaxis: natural history, risk factor analysis, and outcome,” Journal of the American Academy of Dermatology 56(4): 569-579, Elsevier, Netherlands (Apr. 2007).
[cited by applicant]
Wilms, D., et al., “Hyperbranched polyglycerols: from the controlled synthesis of biocompatible polyether polyols to multipurpose applications,” Acc Chem Res 43(1): 129-141, American Chemical Society, United States (Jan…
[cited by applicant]
Zabirnyk, A. i247, NDT Abstract Supplement 2018, Nephrology Dialysis Transplantation, , vol. 33, Issue suppl_1, May 2018, pp. i1-i660.
[cited by applicant]
Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020, accessed at URL:[https://www.sanifit.com/sanifit-to-present-new-data-on-snf472-for-vascular-calcif…
[cited by applicant]
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease, accessed at URL:[https://www.sanifit.com/sanifit-to-start-new-clinical-development-program…
[cited by applicant]
SNF472 Mechanism of Action data published in British Journal of Pharmacology, URL:[https://www.sanifit.com/snf472-mechanism-of-action-data-published-in-british-journal-of-pharmacology/], accessed on Oct. 14, 2020, publi…
[cited by applicant]
Perelló, J., et al. “Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis,” Br J Pharmacol 117(19):4400-4415, Wiley-Blackwell on behalf of the British Pharmaco…
[cited by applicant]
Chertow, G., et al., “SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis,” Novel Approaches to Mineral and Bone Metabolism, Abstract TH-OR18, Kidney Week,…
[cited by applicant]
Sinha, S., et al., “Design of the CALCIPHYX Study, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SNF472 for Treating Calciphylaxis,” Informational Posters, Abstract INFO07, Kidney Week, American Societ…
[cited by applicant]
Perello, J., et al., “Pharmacokinetics, Pharmacodynamics (PK-PD), and Exposure-Efficacy Evaluation from CaLIPSO, a Phase 2B Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification in Patients…
[cited by applicant]
Sussman, C., and Bates-Jensen, B., “Tools to measure wound healing,” In: Wound Care: A Collaborative Practice Manual For Health Professionals, pp. 131-161, Philadelphia, PA, Lippincott Williams & Wilkins, United States …
[cited by applicant]
Ferrer, M. D., et al., “Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification,” PLoS one 13(5):e0197061, Public Library of Science, United States (…
[cited by applicant]
Ferrer, M.D., et al., “A Novel Pharmacodynamic Assay to Evaluate the Effects of Crystallization Inhibitors on Calcium Phosphate Crystallization in Human Plasma,” Scientific Reports 7(1):6858, pp. 1-12, Nature Publishing…
[cited by applicant]
NCT02790073, “Phase 2 Study with SNF472 in Calciphylaxis Patients”, ClinicalTrials.gov, submitted date: Sep. 11, 2017, accessed at https://clinicaltrials.gov/ct2/history/NCT02790073?V_6=View#StudyPageTop, 7 pages.
[cited by applicant]
NCT02966028, “Effect of SNF472 on Progression of Cardiovascular Calicification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)” ClinicalTrials.gov, submitted date: Aug. 29, 2017, accessed at https://clas…
[cited by applicant]
Rocha-Singh, K., et al., “Peripheral Arterial Calcification: Prevalence, Mechanism, Detection, and Clinical Implications,” Catheterization and Cardiovascular Interventions 83(6):E212-E220, Wiley-Liss, United States (May…
[cited by applicant]
Zettervall, S.L., et al., “Association of Arterial Calcification With Chronic Limb Ischemia in Patients With Peripheral Artery Disease,” Journal of Vascular Surgery 67(2):507-513, Elsevier, Netherlands (Feb. 2018).
[cited by applicant]
Alabaz, D., et al., “Unusual Idiopathic Calcinosis Cutis Universalis in a Child,” Case Rep Dermatol 1(1):16-22, Karger, Switzerland (Aug. 2009).
[cited by applicant]
Azpiazu, D., et al., “Role of pyrophosphate in vascular calcification in chronic kidney disease,” Nefrologia (Engl Ed) 38(3):250-257, Elsevier, Spain (May 2018).
[cited by applicant]
Bates-Jensen, B.M., et al., “Validity and Reliability of the Pressure Sore Status Tool,” Decubitus 5(6):20-28, S-N Publications, United States (Nov. 1992).
[cited by applicant]
Efstratiadis, G., et al., “Coronary calcification in patients with end-stage renal disease: a novel endocrine disorder?” Hormones (Athens) 6(2):120-131, Greek Society of Endocrinology, Greece (Apr. 2007).
[cited by applicant]
Higgins, C.L., et al., “Quantification of calcification in atherosclerotic lesions,” Arterioscler Thromb Vasc Biol 25(8):1567-1576, Lippincott Williams & Wilkins, United States (Aug. 2005).
[cited by applicant]
Holt, S.G., and Smith, E.R., “Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease,” Nephrol Dial Transplant 31(10):1583-1587, Oxford University Press, United Kingdom (Oct. 2016).
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2018/057904, European Patent Office, Netherlands, mailed on Apr. 17, 2019, 12 pages.
[cited by applicant]
Jensen, P.S., “Chondrocalcinosis and other calcifications,” Radiol Clin North Am 26(6):1315-1325, Saunders, United States (Nov. 1988).
[cited by applicant]
Lanzer, P., et al., “Medial vascular calcification revisited: review and perspectives,” Eur Heart J 35(23):1515-1525, Oxford University Press, United Kingdom (Jun. 2014).
[cited by applicant]
Liu, Q.L., et al., “Effectiveness of a traditional Chinese medicine, Wulingsan, in suppressing the development of nephrocalcinosis induced by a high phosphorus diet in young rats,” Med Electron Microsc 34(2):103-114, Sp…
[cited by applicant]
Mccarty, M.F., and Dinicolantonio, J.J., “The molecular biology and pathophysiology of vascular calcification,” Postgrad Med 126(2):54-64, Taylor & Francis, United Kingdom (Mar. 2014).
[cited by applicant]
Nicoll, R., and Henein, M.Y., “The predictive value of arterial and valvular calcification for mortality and cardiovascular events,” Int J Cardiol Heart Vessel 3:1-5, Elsevier, Netherlands (Feb. 2014).
[cited by applicant]
Orzechowska, S., et al., “Physicochemical and micro-tomographic characterization of inorganic deposits associated with aortic stenosis,” J Heart Valve Dis 23(1):40-47, ICR Publishers, United States (Jan. 2014).
[cited by applicant]
Otero, J.E., et al., “Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy,” J Bone Miner Res 28(2):419-430, American Society for Bone and Mineral Research, Unite…
[cited by applicant]
Perelló, J., et al., “SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels,” J Nephrol 31(2):287-296, Springer Nature, Germany (…
[cited by applicant]
Rez, P., “What does the crystallography of stones tell us about their formation?” Urolithiasis 45(1):11-18, Springer Nature, Germany (Feb. 2017).
[cited by applicant]
Vervaet, B.A., et al., “An active renal crystal clearance mechanism in rat and man,” Kidney Int 75(1):41-51, Elsevier, Netherlands (Jan. 2009).
[cited by applicant]
Ziegler, S.G., et al., “Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase,” Sci Transl Med 9(393):eaal1669, American Association for the Advancement of S…
[cited by applicant]
U.S. Appl. No. 18/778,767, Perello Bestard, J., et al., filed Jul. 19, 2024 (Not Published). (Now Abandoned).
[cited by applicant]
Adragao, T., et al., “A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients,” Nephrol Dial Transplant 24(3):997-1002, Oxford University Press, United Kingdom…
[cited by applicant]
Agatston, A.S., et al., “Quantification of coronary artery calcium using ultrafast computed tomography,” J Am Coll Cardiol 15(4):827-832, Elsevier, Netherlands (Mar. 1990).
[cited by applicant]
Aleti, S., “Types, Causes and Risk Factors of Peripheral Artery Disease,” Heart and Vascular Care Screenings And Diagnostics, Orlando Health (Jul. 2018), 3 Pages.
[cited by applicant]
Amann, K., “Media Calicification and Intima Calcification are Distinct Entities in Chronic Kidney Disease,” Clinical Journal of the American Society of Nephrology 3(6):1599-605, The American Society of Nephrology, Unite…
[cited by applicant]
Ariyoshi, T., et al., “Effect of Etidronic Acid on Arterial Calcification in Dialysis Patients,” Clinical Drug Investigation 26(4):215-222, Springer International, New Zealand (Apr. 2006).
[cited by applicant]
Bellasi, A., et al. “Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients,” Kidney Int 70(9):1623-1628, Elsevier, Netherlands (Nov. 2006).
[cited by applicant]
Berg, C.J.V.D., et al., “Inositol Phosphates and Phytic Acid as Inhibitors of Biological Calcification in the Rat,” Clinical Science 43(3):377-383, Blackwell Scientific Publications, United Kingdom (Sep. 1972).
[cited by applicant]
Blacher, J., et al., “Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-stage Renal Disease,” Hypertension 38(4):938-942, Lippincott Williams & Wilkins, United States (Oct. 2001).
[cited by applicant]
Blaha, M.J., “Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study,” Lancet 378(9792):684-692, E…
[cited by applicant]
Blaha, M.J., et al., “Improving the CAC Score by Addition of Regional Measures of Calcium Distribution,” JACC Cardiovasc Imaging 9(12): 1407-1416, Elsevier, United States (Dec. 2016).
[cited by applicant]
Bloom, J.R., and Navon, J.R., “Inhibitory Effect of Phytate on Bone Resorption in Organ Cultures,” Journal of Dental Research 63(6):890-893, Sage, United States (1979).
[cited by applicant]
Boucher, L., et al., “Internalization and Distribution of Inositol Hexakisphosphate in Red Blood Cells,” Biotechnology and Applied Biochemistry 24(Pt 1):73-78, Academic Press, United States (Aug. 1996).
[cited by applicant]
Bourgeaux. V., et al., “Efficacy of homologous inositol hexaphosphate-loaded red blood cells in sickle transgenic mice,” British Journal of Haematology 157(3):357-369, Blackwell Publishing Ltd., United Kingdom (May 2012…
[cited by applicant]
Brandenburg, V.M., et al., “Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis,” J Nephrol 32(5):811-821, Springer Natur…
[cited by applicant]
Brown, A.J., “Role of biomechanical forces in the natural history of coronary atherosclerosis,” Nat Rev Cardiol 13(4):210-220, Nature Portfolio, United Kingdom (Apr. 2016).
[cited by applicant]
Budoff, M.J., et al., “Progression of coronary artery calcium predicts all-cause mortality,” JACC Cardiovasc Imaging 3(12):1229-1236, Elsevier, Netherlands (Dec. 2010).
[cited by applicant]
Callister, T.Q., et al., “Coronary Artery Disease: Improved Reproducibility of Calcium Scoring with an Electron-beam CT Volumetric Method,” Radiology 208(3):807-814, Radiological Society of North America, United States …
[cited by applicant]
Chen, J., et al., “Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease,” JAMA Cardiology 2(6):635-643, American Medical Association, United States (Jun. …
[cited by applicant]
Chertow, G.M., et al., “Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients,” Kidney Int 62(1):245-252, Elsevier, Netherlands (Jul. 2002).
[cited by applicant]
ClinicalTrials., “Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD),” NCT02966028, accessed at https://clinicaltrials.gov/study/NCT02966028?c…
[cited by applicant]
Conte, A., et al., “Urinary Lithogen Risk Test: Usefulness in the Evaluation of Renal Lithiasis Treatment Using Crystallization Inhibitors (Citrate and Phytate),” Archivos Espannoles De Urologiia 52(3):305-310, Iniestar…
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/053,226, inventors Perello Bestard, J., et al., filed Feb. 13, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/065,816, inventors Bassissi, M.F., et al., filed Feb. 27, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/355,714, inventors Bassissi, M.F., et al., filed Oct. 10, 2025 (Not yet Published).
[cited by applicant]
Cozzolino, M., et al., “Cardiovascular disease in dialysis patients,” Nephrol Dial Transplant 33(Suppl 3):iii28-iii34, Oxford University Press, United Kingdom (Oct. 2018).
[cited by applicant]
Davita, “Kidney Stones and Chronic Kidney Disease,” accessed at http://www.davita.com/kidney-disease/overview/symptoms-and-diagnosis/kidney-stones-a . . . , accessed on on Nov. 5, 2015, 1 page.
[cited by applicant]
Di Iorio, B., et al., “Coronary Artery Calcification Progression is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients,” Kidney & Blood Pressure Research 34(3):180-187, …
[cited by applicant]
Disthabanchong, S., et al., “Abdominal Aorta and Pelvic Artery Calcifications on Plain Radiographs may Predict Mortality in Chronic Kidney Disease, Hemodialysis and Renal Transplantation,” International Urology and Neph…
[cited by applicant]
Ditmar, R., and Steidl, L., “The Importance of Magnesium in Orthopedics. Vi. The Importance of Magnesium in the Treatment of Ectopic Calcification and Ossification,” Acta Chirurgiae Orthopaedicae Et Traumatologiae Cecho…
[cited by applicant]
Einck, L., and Holaday. J.W., “Enhancement of Tissue Oxygenation By Intracellular Introduction of Inositol Hexaphosphate By Flow Electroporation of Red Blood Cells,” Update in Intensive Care And Emergency Medicine, Tiss…
[cited by applicant]
Final Office Action mailed Nov. 9, 2015, in U.S. Appl. No. 14/212,286, Perello Bestard, J., et al., filed Mar. 14, 2014, 18 pages.
[cited by applicant]
Final Office Action mailed Sep. 1, 2020, in U.S. Appl. No. 16/209,150, Perello Bestard, J., et al., filed Dec. 4, 2018, 16 pages.
[cited by applicant]
Final Office Action mailed Sep. 7, 2021, in U.S. Appl. No. 16/209,150, Perello Bestard, J., et al., filed Dec. 4, 2018, 11 pages.
[cited by applicant]
Final Office Action mailed Jan. 23, 2023, in U.S. Appl. No. 17/728,807, Perello Bestard, J., et al., filed Apr. 25, 2022, 11 pages.
[cited by applicant]
Foley, R.N., et al., “Clinical Epidemiology of Cardiovascular Disease in Chronic Renal Disease,” American Journal of Kidney Diseases 32(5 Suppl 3):S112-119, Elsevier, Netherlands (Nov. 1998).
[cited by applicant]
Gomes, B.C., et al., “Inhibitory Effect of Inositol Phosphates on Parathyroid Hormone-induced Bone Resorption in Organ Cultures,” Journal of Dental Research 63(6):890-893, Sage, United States (Jun. 1984).
[cited by applicant]
Grases, F., and Costa-Bauza, A., “Potentiometric Study of the Nucleation of Calcium Oxalate in Presence of Several Additives,” Clinical Chemistry and Enzymology Communications 3:319-328, The Harwood Academic Publishers,…
[cited by applicant]
Grases, F., et al., “A New Procedure to Evaluate the Inhibitory Capacity of Calcium Oxalate Crystallization in Whole Urine,” International Urology and Nephrology 27(6):653-661, Springer, Netherlands (1995).
[cited by applicant]
Grases, F., et al., “Absorption of Myo-inositol Hexakisphosphate (InsP6) Through the Skin in Humans,” Die Pharmazie 61(7):652, Govi-Verlag Pharmazautischer Verlag, Germany (Jul. 2006).
[cited by applicant]
Grases, F., et al., “Anticalculus Effect of a Triclosan Mouthwash Containing Phytate: A Double-blind, Randomized, Three-period Crossover Trial,” Journal of Periodontal Research 44(5):616-621, Wiley-Blackwell, United Sta…
[cited by applicant]
Grases, F., et al., “Artificial Simulation of the Early Stages of Renal Stone Formation,” British Journal of Urology 74(3):298-301, Blackwell Science, United Kingdom (Sep. 1994).
[cited by applicant]
Grases, F., et al., “Dietary Myo-inositol Hexaphosphate Prevents Dystrophic Calcifications in Soft Tissues: A Pilot Study in Wistar Rats,” Life Sciences 75(1):11-19, Elsevier, Netherlands (May 2004).
[cited by applicant]
Grases, F., et al., “Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D: A Pilot Study in Sprague-Dawley Rats,” Circulation Journal 71(7):1152-1156, Japanese Circulation Society, Japan …
[cited by applicant]
Grases, F., et al., “Phytate Inhibits Bovine Pericardium Calcification in Vitro,” Cardiovascular Pathology 17(3):139-145, Elsevier Science Pub. Co., United States (May-Jun. 2008).
[cited by applicant]
Grases, F., et al., “Phytate Prevents Tissue Calcifications in Female Rats,” BioFactors 11(3):171-177, Wiley, United States (2000).
[cited by applicant]
Grases, F., et al., “Studies on Calcium Oxalate Monohydrate Crystallization: Influence of Inhibitors,” Urological Research 22(1):39-43, Springer-Verlag, Germany (Apr. 1994).
[cited by applicant]
Grases, F., et al., “Study of a Myo-inositol Hexaphosphate-based Cream to Prevent Dystrophic Calcinosis Cutis,” The British Journal of Dermatology 152(5):1022-1025, Oxford University Press, United Kingdom (May 2005).
[cited by applicant]
Grases, F., et al., “Study of the Absorption of Myo-inositol Hexakisphosphate (InsP6) Through the Skin,” Biological & Pharmaceutical Bulletin 28(4):764-767, Pharmaceutical Society of Japan, Japan (Apr. 2005).
[cited by applicant]
Grases, F., et al., “Study of the Effects of Different Substances on the Early Stages of Papillary Stone Formation,” Nephron 73(4):561-568, Karger, Switzerland (Jan. 1996).
[cited by applicant]
Grau., et al., “Relationship Between Phytate and Valvular Heart Calcifications. Field Study To Design a Clinical Assay About Aortic Stenosis,” Sanifit Laboratory.
[cited by applicant]
Halvorson, K.G., et al., “Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer,” Journal of Pain and Sympto…
[cited by applicant]
Hamburg, N.M., and Balady G.J., “Exercise Rehabilitation in Peripheral Artery Disease: Functional Impact and Mechanisms of Benefits,” Circulation 123(1):87-97, Lippincott Williams & Wilkins, United States (Jan. 2011).
[cited by applicant]
Hippocrates, Y., and Agroyannis, B., et al., “Sodium Thiosulfate Treatment of Soft-tissue Calcifications in Patients With End-stage Renal Disease,” Peritoneal Dialysis International 7(4):250-252, SAGE Publications, Unit…
[cited by applicant]
Howard, G., et al., “Does the Association of Risk Factors and Atherosclerosis Change With Age? An Analysis of the Combined ARIC and CHS Cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health S…
[cited by applicant]
Inhibit, “Definition of Inhibit by the Free Dictionary,” accessed at http://www.thefreedictionary.com/inhibit, accessed on Feb. 28, 2018, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2020/081674, European Patent Office, Netherlands, mailed on Oct. 2, 2021, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/ES2020/070070, European Patent Office, Netherlands, mailed on May 12, 2020, 16 pages.
[cited by applicant]
Jamal, S.A., et al., “Effect of Calcium-based Versus non-calcium-based Phosphate Binders on Mortality in Patients with Chronic Kidney Disease: An Updated Systematic Review and Meta-analysis,” Lancet 382(9900):1268-1277,…
[cited by applicant]
James, C.A., et al., “Pediatric Case of the Day. Klippel-Trenaunay Syndrome,” Radiographics 19(4):1093-1096, Radiological Society of North America, United States (Jul.-Aug. 1999).
[cited by applicant]
Jean, G., et al., “Peripheral Vascular Calcification in Long-haemodialysis Patients: Associated Factors and Survival Consequences,” Nephrology, Dialysis, Transplantation 24(3):948-955, Oxford University Press, United Ki…
[cited by applicant]
Johnson, R.C., “Vascular calcification: pathobiological mechanisms and clinical implications,” Cut Res 99(10):1044-59, Lippincott Williams & Wilkins, United States (Nov. 2006).
[cited by applicant]
Kobayashi, S., “Cardiovascular Events in Hemodialysis Patients: Challenging Against Vascular Calcification,” Journal of the Japanese Society of Vascular Surgery, 25:359-365, Japanese Society for Vascular Surgery, Japan …
[cited by applicant]
Kalantar-Zadeh, K., et al., “Understanding Sources of Dietary Phosphorus in the Treatment of Patients With Chronic Kidney Disease,” Clinical Journal of the American Society of Nephrology 5(3):519-530, Wolters Kluwer Hea…
[cited by applicant]
Karohl, C., et al., “Hybrid myocardial imaging for risk stratification prior to kidney transplantation: added value of coronary calcium and epicardial adipose tissue,” J Nucl Cardiol 20(6): 1013-1020, Springer Science+B…
[cited by applicant]
Kasting, G.B., et al. “Skin Penetration Enhancement Methods for Hydrophilic Compounds,” Pharmaceutical Research 14(Suppl_11):S452 (Nov. 1997), ISSN: 0724-8741.
[cited by applicant]
Kaufman, H.W., “Interactions of Inositol Phosphates with Mineralized Tissues,” in
[cited by applicant]
Kim, T.I., and Guzman, R.J., “The Role of Calcification in Peripheral Artery Disease,” Chapter 8 in Cardiovascular Calcification and Bone Mineralization, Aikawa, E., and Hutcheson, J.D., eds., pp. 167-183, Springer Natu…
[cited by applicant]
Kishimoto, Y., et al., “Plasma Heme Oxygenase-1 Levels in Patients with Coronary and Peripheral Artery Diseases,” Disease Markers 2018:6138124, Wiley, United States (Aug. 2018), 8 pages.
[cited by applicant]
Kitamura, K., et al., “Relationship Between Cardiac Calcification and Left Ventricular Hypertrophy in Patients with Chronic Kidney Disease at Hemodialysis Initiation,” Heart Vessels 32(9):1109-1116, Springer Nature, Ger…
[cited by applicant]
Kovacs, A., et al., “Ultrastructure and Composition of Thrombi in Coronary and Peripheral Artery Disease: Correlations with Clinical and Laboratory Findings,” Thrombosis Research 135:760-766, Elsevier, Netherlands (Apr.…
[cited by applicant]
Kwon, H.Y., et al., “The association between mortality and abdominal aortic calcification and relation between its progression and serum calcium concentration in chronic hemodialysis patients,” Kidney Res Clin Pract 33(…
[cited by applicant]
Lo, G.S., et al., “Effect of Phytate:zinc Molar Ratio and Isolated Soybean Protein on Zinc Bioavailability,” The Journal of Nutrition 111(12):2223-2235, Elsevier, United States (Dec. 1981).
[cited by applicant]
Marwick, T.H., et al., “Chronic Kidney Disease and Valvular Heart Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference,” Kidney International 96(4):836-849, Elsevier, Ne…
[cited by applicant]
Mcdermott, M.M., “Functional Impairment in Peripheral Artery Disease and How to Improve It in 2013,” Current Cardiology Reports 15(4):347, Current Science, United States (Apr. 2013), 13 pages.
[cited by applicant]
Merriam-Webster, Inc, “Merriam-Webster's Collegiate Dictionary,” Tenth Edition, p. 924, Springfield, United States (1998), 3 pages.
[cited by applicant]
Merriam-Webster, “Prevention,” accessed at http://www.merriam-webster.com/dictionary/prevention, accessed on Feb. 7, 2015, 1 page.
[cited by applicant]
Miyazaki, Y., et al., “Low Plasma. Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease,” Journal of Atherosclerosis and Thrombosis 25:821-828, Japan Atherosclerosis Society, Japan (Sep. 2018…
[cited by applicant]
Nambi, V., et al., “Differences in Responses of Platelets to Fluid Shear Stress in Patients with Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD),” Platelets 20(3):199-205, Elsevier, Netherlands (May 20…
[cited by applicant]
Nancollas, G.H., et al., “Novel Insights Into Actions of Bisphosphonates on Bone: Differences in Interactions With Hydroxyapatite,” Bone 38(5):617-627, Elsevier Science, United States (May 2006).
[cited by applicant]
NCT02966028, “Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD),” (2016), accessed at https://clinicaltrials.gov/ct2/show/NCT02966028, access…
[cited by applicant]
NCT02966028, “Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD),” Study Record Version 54 (2019), accessed at https://clinicaltrials.gov/stud…
[cited by applicant]
Non-Final Office Action mailed May 6, 2015, in U.S. Appl. No. 14/212,286, Perello Bestard, J., et al., filed Mar. 14, 2014, 20 pages.
[cited by applicant]
Non-Final Office Action mailed Jul. 3, 2017, in U.S. Appl. No. 15/163,366, Perello Bestard, J., et al., filed May 24, 2016, 21 pages.
[cited by applicant]
Non-Final Office Action mailed Feb. 17, 2022, in U.S. Appl. No. 16/209,150, Perello Bestard, J., et al., filed Dec. 4, 2018, 13 pages.
[cited by applicant]
Non-Final Office Action mailed Mar. 20, 2020, in U.S. Appl. No. 16/209,150, Perello Bestard, J., et al., filed Dec. 4, 2018, 20 pages.
[cited by applicant]
Non-Final Office Action mailed Mar. 30, 2021, in U.S. Appl. No. 16/209,150, Perello Bestard, J., et al., filed Dec. 4, 2018, 12 pages.
[cited by applicant]
Non-Final Office Action mailed Oct. 12, 2022, in U.S. Appl. No. 17/728,807, Perello Bestard, J., et al., filed Apr. 25, 2022, 12 pages.
[cited by applicant]
Non-Final Office Action mailed Aug. 15, 2024, in U.S. Appl. No. 18/357,004, Perello Bestard, J., et al., filed Jul. 21, 2023, 12 pages.
[cited by applicant]
Notice of Allowance mailed Feb. 17, 2016, in U.S. Appl. No. 14/212,286, Perello Bestard, J., et al., filed Mar. 14, 2014, 11 pages.
[cited by applicant]
Notice of Allowance mailed Mar. 2, 2018, in U.S. Appl. No. 15/163,366, Perello Bestard, J., et al., filed May 24, 2016, 9 pages.
[cited by applicant]
Okuno, S., et al., “Presence of Abdominal Aortic Calcification is Significantly Associated with All-cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients,” American Journal of Kidney Diseases 49(3):417…
[cited by applicant]
O'neill, W.C., et al., “Prevalence of Nonatheromatous Lesions in Peripheral Arterial Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology 35(2):439-447, American Heart Association, United States (Dec. 2014).
[cited by applicant]
Pasch, A., et al., “Nanoparticle-based Test Measures Overall Propensity for Calcification in Serum,” Journal of the American Society of Nephrology 23(10):1744-1752, Wolters Kluwer Health, United States (Oct. 2012).
[cited by applicant]
Patel, L., et al., “Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials,” Clin J Am Soc Nephrol 11(2):232-244, American Society of Nephrology…
[cited by applicant]
Raggi, P., et al., “Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients,” Kidney Int 71(8):802-807, Elsevier, Netherlands (Apr. 2007).
[cited by applicant]
Raggi, P., et al., “Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease,” Journal of the American College of Cardiology 39(4):695-701, American College…
[cited by applicant]
Raggi, P., et al., “Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis,” Nature Clinical Practice. Cardiovascular Medicine 4(1):26-33, Nature Portfolio, Unit…
[cited by applicant]
Raggi, P., et al., “The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis,” Nephrol Dial Transplant 26(4):1327-1339, Ox…
[cited by applicant]
Rao, P.S., et al., “Protection of Ischemic Heart From Reperfusion Injury by Myo-inositol Hexaphosphate, A Natural Antioxidant,” The Annals of Thoracic Surgery 52(4):908-912, Elsevier, Netherlands (Oct. 1991).
[cited by applicant]
Rein, P., et al., “Systemic Inflammation is Higher in Peripheral Artery Disease Than in Stable Coronary Artery Disease,” Atherosclerosis 239(2):299-303, Elsevier, Ireland (Apr. 2015).
[cited by applicant]
Reiter, N., et al., “Calcinosis Cutis Part I. Diagnostic Pathway,” Journal of the American Academy of Dermatology 65:1-12, St. Louis, MO, United States (Jul. 2011).
[cited by applicant]
Sadek, T., “Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study,” Nephrol Dial Transplant 18(3):582-588, Oxford Un…
[cited by applicant]
Saeki, T., et al., “Inositol-1,4,5-trisphosphate Increases Contractions but Not L-type Calcium Current in Guinea Pig Ventricular Myocytes,” Cardiovascular Research 41(3):620-628, Oxford Journals, United Kingdom (Mar. 19…
[cited by applicant]
Sanifit, “Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis,” BioSpace.com, accessed at https://w…
[cited by applicant]
Shao, U.S., et al., “Molecular Mechanisms of Vascular Calcification: Lessons Learned from the Aorta,” Arteriosclerosis, Thrombosis, and Vascular Biology 26(7):1423-1430, American Heart Association, United States (Jul. 2…
[cited by applicant]
Steidl, L., and Ditmar, R., “Soft Tissue Calcification Treated With Local and Oral Magnesium Therapy,” Magnesium Research 3(2):113-119, John Libbey And Company, United Kingdom (Jun. 1990).
[cited by applicant]
Straub, M., and Hautmann, R.E., “Developments in Stone Prevention,” Current Opinion in Urology 15(2):119-126, Lippincott Williams & Wilkins, United States (Mar. 2005).
[cited by applicant]
Sullivan, B.J., and Flynn. P.M., “Influence of Inositol on Peripheral Vascular Responses to Cold Injury,” Proceedings of the Society for Experimental Biology and Medicine 94(2):346-347, SAGE Publishing, United States (F…
[cited by applicant]
Tripathi, A.K., et al., “Soybean—A Consummate Functional Food: A Review,” Journal of Food Sciences and Technology 42(2):111-119, Springer Nature, Germany (2005).
[cited by applicant]
Van Der Kaay, J., and Van Haastert, P.J., “Desalting Inositolpolyphosphates by Dialysis,” Analytical Biochemistry 225(1):183-185, Elsevier, United States (Feb. 1995).
[cited by applicant]
Verbeke, F., et al., “Prognostic Value of Aortic Stiffness and Calcification for Cardiovascular Events and Mortality in Dialysis Patients: Outcome of the Calcification Outcome in Renal Disease (CORD) Study,” Clinical Jo…
[cited by applicant]
Westerling, D., et al., “Postoperative Recovery After Cholecystectomy by Minilaparotomy: A Randomized Double-blind Comparison Between Alpha-trinositol and Placebo,” Pharmacology & Toxicology 81(6):253-258, Elsevier, Net…
[cited by applicant]
Zabirnyk, A., et al., “SNF472, A Novel Anti-crystallization Agent, Inhibits Induced Calcification in an in Vitro Model of Human Aortic Valve Calcification,” Vascular Pharmacology 122-123:106583, Elsevier Science, United…
[cited by applicant]